Benitec Biopharma Limited announced the appointment of Mr. Greg West as Chief Executive Officer, Dr. Cliff Holloway to the combined role of Chief Business and Operating Officer and Mr. Bryan Dulhunty as Chief Financial Officer. Mr. West was previously appointed interim CEO on 9 December 2015, and had been the Chief Financial Officer and Company Secretary of Benitec since 2011. Dr. Cliff Holloway, who will be based in the United States, will join the company on 24 August 2016 as Chief Business and Operating Officer.

Cliff has previously served as CEO and Managing Director of Sienna Cancer Diagnostics Limited, Immune System Therapeutics Limited, and Biosceptre International Limited. He was formerly VP Business Development at ASX listed biotechnology company Arana Therapeutics Limited, which was acquired by Cephalon Inc. (now Teva Pharmaceuticals) in 2009. Mr. Bryan Dulhunty commenced in his new role as CFO on 1 July 2016.

Bryan has 20 years' experience in the life sciences sector, and has previously served as Executive Chairman, Non-Executive Director, Managing Director, CFO and Company Secretary of a number of listed and non-listed biotech companies. Bryan holds a Bachelor of Economics from the University of Sydney and is a Chartered Accountant. Mr. Carl Stubbings, the previous Chief Business Officer, left the company, effective 31 July, to pursue other opportunities.